PBYI · CIK 0001401667 · operating
Puma Biotechnology is a biopharmaceutical company focused on oncology therapeutics for breast cancer and other solid tumors. The company's primary commercial product is NERLYNX (neratinib), an oral HER2-targeted therapy approved for early-stage HER2-overexpressed/amplified breast cancer and advanced or metastatic HER2-positive breast cancer in combination with capecitabine. The company also develops alisertib, a small molecule aurora kinase A inhibitor in clinical development for hormone receptor-positive breast cancer, triple-negative breast cancer, small cell lung cancer, and head and neck cancer.
Revenue is generated through NERLYNX sales, distributed via specialty pharmacy and distributor networks. Puma operates under license agreements with Pfizer for neratinib and related compounds, with sub-licensing arrangements extending geographic reach across multiple regions through partners including Knight Therapeutics, Pierre Fabre Medicament, and others. The company maintains research and development operations supporting its pipeline programs.
Based in Los Angeles, California, Puma Biotechnology operates as a mid-sized biopharmaceutical entity with a market capitalization of approximately $0.4 billion. The company distributes products internationally while maintaining primary commercial focus in the United States market.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.61 | $0.62 | -1.6% | |
| 2024 | $0.62 | $0.62 | +37.8% | |
| 2023 | $0.45 | $0.46 | — | |
| 2022 | $0.00 | $0.00 | +100.0% | |
| 2021 | — | $-29126.00 | -7664636.8% | |
| 2020 | $-0.38 | $-0.38 | — | |
| 2019 | — | — | — | |
| 2018 | — | — | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001437749-26-005891 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0001437749-25-005496 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001437749-24-006121 | SEC ↗ |
| 2022-12-31 | 2023-03-02 | 0001437749-23-005233 | SEC ↗ |
| 2021-12-31 | 2022-03-03 | 0001437749-22-005164 | SEC ↗ |
| 2020-12-31 | 2021-03-01 | 0001564590-21-009840 | SEC ↗ |
| 2019-12-31 | 2020-02-28 | 0001564590-20-007591 | SEC ↗ |
| 2018-12-31 | 2019-03-01 | 0001564590-19-005830 | SEC ↗ |
| 2017-12-31 | 2018-03-09 | 0001564590-18-005152 | SEC ↗ |
| 2016-12-31 | 2017-03-01 | 0001564590-17-003090 | SEC ↗ |
| 2015-12-31 | 2016-02-29 | 0001564590-16-013716 | SEC ↗ |
| 2014-12-31 | 2015-03-02 | 0001564590-15-001193 | SEC ↗ |
| 2013-12-31 | 2014-03-03 | 0001193125-14-080183 | SEC ↗ |
| 2012-12-31 | 2013-04-01 | 0001193125-13-136650 | SEC ↗ |